Gouty Arthritis (Gout) - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 105 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) - Pipeline Review, H2 2016, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 3, 14, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Gouty Arthritis (Gout).

Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Gouty Arthritis (Gout) Overview 10
Therapeutics Development 11
Pipeline Products for Gouty Arthritis (Gout) - Overview 11
Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis 12
Gouty Arthritis (Gout) - Therapeutics under Development by Companies 13
Gouty Arthritis (Gout) - Therapeutics under Investigation by Universities/Institutes 15
Gouty Arthritis (Gout) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Gouty Arthritis (Gout) - Products under Development by Companies 20
Gouty Arthritis (Gout) - Products under Investigation by Universities/Institutes 22
Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development 23
Allena Pharmaceuticals, Inc. 23
AstraZeneca Plc 24
C&C Research Laboratories 25
Cell Medica Limited 26
Immune Response BioPharma, Inc. 27
IOmet Pharma 28
Jiangsu Hengrui Medicine Co., Ltd. 29
LG Life Science LTD. 30
Monosol Rx LLC 31
Nimbus Therapeutics, LLC 32
Opsona Therapeutics Limited 33
Polaris Pharmaceuticals, Inc. 34
ProteoThera, Inc. 35
Selvita S.A. 36
Swedish Orphan Biovitrum AB 37
Teijin Pharma Limited 38
TWi Pharmaceuticals, Inc. 39
Wellstat Therapeutics Corporation 40
XL-protein GmbH 41
Gouty Arthritis (Gout) - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
ALLN-346 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
anakinra - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
APP-112 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
AQB-565 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
AXIBU-03 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
colchicine - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
diacerein - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
DLX-2323 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
DLX-2681 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
febuxostat - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
IR-888 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
LC-350189 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Respiratory Infections - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
ND-2110 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
ND-2158 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
ND-346 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
pegadricase - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
PRT-1000 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
REV-002 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
RLBN-1001 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
SEL-212 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
SHR-4640 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Small Molecule Inflammasome Modulator Programme - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Small Molecules to Inhibit GLUT9 for Gout - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
TMX-049 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
URC-102 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
uriSHELS - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
verinurad - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
WT-2107 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
XEN-102 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
XEN-104 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
XL-400 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Gouty Arthritis (Gout) - Dormant Projects 90
Gouty Arthritis (Gout) - Discontinued Products 93
Gouty Arthritis (Gout) - Product Development Milestones 94
Featured News & Press Releases 94
Oct 26, 2016: Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout 94
Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment 95
May 10, 2016: Revive Therapeutics Provides Clinical and Corporate Update 95
Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra) 96
Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra) 96
Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients 97
Dec 23, 2015: Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout 98
Oct 19, 2015: MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery 99
Sep 30, 2015: Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 in the Treatment of Acute Gout Flares 99
Jun 30, 2015: New Indication for Teijin Pharma's Febuxostat in Europe 100
Jun 10, 2015: Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout 101
Feb 27, 2015: Stiris Research Awarded a Phase IIa Trial in Gout 101
Feb 26, 2015: Revive Therapeutics Expands its Orphan Drug Indication Pipeline to Include Cystinuria and Wilson Disease 101
Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan 102
Nov 26, 2014: Revive Therapeutics Announces US FDA Acceptance of IND to Commence Clinical Trial for Bucillamine for the Treatment of Gout 102
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 104
Disclaimer 105

List of Tables

Number of Products under Development for Gouty Arthritis (Gout), H2 2016 11
Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Comparative Analysis by Unknown Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2016 22
Gouty Arthritis (Gout) - Pipeline by Allena Pharmaceuticals, Inc., H2 2016 23
Gouty Arthritis (Gout) - Pipeline by AstraZeneca Plc, H2 2016 24
Gouty Arthritis (Gout) - Pipeline by C&C Research Laboratories, H2 2016 25
Gouty Arthritis (Gout) - Pipeline by Cell Medica Limited, H2 2016 26
Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma, Inc., H2 2016 27
Gouty Arthritis (Gout) - Pipeline by IOmet Pharma, H2 2016 28
Gouty Arthritis (Gout) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 29
Gouty Arthritis (Gout) - Pipeline by LG Life Science LTD., H2 2016 30
Gouty Arthritis (Gout) - Pipeline by Monosol Rx LLC, H2 2016 31
Gouty Arthritis (Gout) - Pipeline by Nimbus Therapeutics, LLC, H2 2016 32
Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Limited, H2 2016 33
Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 34
Gouty Arthritis (Gout) - Pipeline by ProteoThera, Inc., H2 2016 35
Gouty Arthritis (Gout) - Pipeline by Selvita S.A., H2 2016 36
Gouty Arthritis (Gout) - Pipeline by Swedish Orphan Biovitrum AB, H2 2016 37
Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Limited, H2 2016 38
Gouty Arthritis (Gout) - Pipeline by TWi Pharmaceuticals, Inc., H2 2016 39
Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corporation, H2 2016 40
Gouty Arthritis (Gout) - Pipeline by XL-protein GmbH, H2 2016 41
Assessment by Monotherapy Products, H2 2016 42
Number of Products by Stage and Target, H2 2016 44
Number of Products by Stage and Mechanism of Action, H2 2016 46
Number of Products by Stage and Route of Administration, H2 2016 48
Number of Products by Stage and Molecule Type, H2 2016 50
Gouty Arthritis (Gout) - Dormant Projects, H2 2016 90
Gouty Arthritis (Gout) - Dormant Projects (Contd..1), H2 2016 91
Gouty Arthritis (Gout) - Dormant Projects (Contd..2), H2 2016 92
Gouty Arthritis (Gout) - Discontinued Products, H2 2016 93